OMERS ADMINISTRATION Corp Sells 4,100 Shares of Charles River Laboratories International, Inc. $CRL

OMERS ADMINISTRATION Corp trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 7.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,429 shares of the medical research company’s stock after selling 4,100 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Charles River Laboratories International were worth $9,389,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of CRL. Jones Financial Companies Lllp boosted its stake in Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Charles River Laboratories International in the first quarter valued at $418,000. American Century Companies Inc. raised its holdings in shares of Charles River Laboratories International by 41.9% in the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after buying an additional 1,616 shares during the last quarter. Brown Advisory Inc. raised its holdings in shares of Charles River Laboratories International by 5.1% in the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after buying an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System lifted its position in Charles River Laboratories International by 3.9% during the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after buying an additional 3,198 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $226.38 on Monday. The business’s 50-day simple moving average is $198.80 and its 200 day simple moving average is $187.36. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The stock has a market cap of $10.90 billion, a price-to-earnings ratio of -60.21, a P/E/G ratio of 2.52 and a beta of 1.40. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $238.85.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same period in the previous year, the business posted $2.34 EPS. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on CRL shares. CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a report on Monday, July 20th. Evercore reaffirmed an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Mizuho upped their target price on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price target on the stock. Finally, Morgan Stanley raised their price target on shares of Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $220.75.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.